This is a working overview of half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Stolen Focus: Why You Can't Pay Attention was published in the UK on January 6th, 2022, followed by the US on January 25th the same month. In Stolen Focus, Hari argues that elements of modern lifestyles, including smart phones and social media, are "destroying our ability to concentrate." The book also discusses opinions on chronic stress, a decrease in outdoor play among children, and the potential effect of ultra-processed foods on brain functions. Stolen Focus debuted at number seven on the New York Times nonfiction best-seller list for the week ending 12 February 2022. The original UK and US releases of Stolen Focus have different subtitles. The full title of the UK edition reads: Stolen Focus: Why You Can't Pay Attention, while the US edition continues this subtitle: Stolen Focus: Why You Can't Pay Attention—and How to Think Deeply Again.
=== Category:EC 3.4 (act on peptide bonds - Peptidase) === Category:EC 3.4.11 Alanine aminopeptidase Category:EC 3.4.15 Angiotensin converting enzyme Category:EC 3.4.21 Serine protease Chymotrypsin (EC 3.4.21.1) Trypsin (EC 3.4.21.4) Thrombin (EC 3.4.21.5) Factor X (EC 3.4.21.6) Plasmin (EC 3.4.21.7) Acrosin (EC 3.4.21.10) Factor VII (EC 3.4.21.21) Factor IX (EC 3.4.21.22) Prolyl oligopeptidase (EC 3.4.21.26) Factor XI (EC 3.4.21.27) Elastase (EC 3.4.21.37) Factor XII (EC 3.4.21.38) Proteinase K (EC 3.4.21.64) Tissue plasminogen activator (EC 3.4.21.68) Protein C (EC 3.4.21.69) Category:EC 3.4.22 Separase (EC 3.4.22.49) Category:EC 3.4.23 Pepsin (EC 3.4.23.1) Rennet (EC 3.4.23.4) Renin (EC 3.4.23.15) Trypsinogen (EC 3.4.23.18) and (20/21/23/24/26) Plasmepsin (EC 3.4.23.39) Category:EC 3.4.24 Matrix metalloproteinase (EC 3.4.24.7) Category:EC 3.4.25 Metalloendopeptidase
==== pRNA ==== Bacteriophage φ29 prohead RNA (pRNA) has the ability to form quaternary structure. pRNA is able to form into a quaternary structure by oligimerizing to create the capsid that encloses the genomic DNA of bacteriophage. Several molecules of pRNA surround the genome, and through stacking interactions and base pairing the pRNAs enclose and the protect the DNA. Crystallography studies show that pRNA forms tetrameric rings, although cryo-EM structures suggest pRNA may also form pentameric rings.
== Government investment and oversight == Between 2020 and 2024, the Ugandan government invested approximately UGX 723.4 billion in Dei BioPharma through multiple budget allocations. The investment sparked parliamentary scrutiny, with the Leader of the Opposition, Joel Ssenyonyi, questioning the absence of key documents such as a valuation by the Chief Government Valuer and a formal memorandum of understanding. The Auditor General’s report further raised concerns about the lack of share certificates and valuation documentation. In response to mounting questions, the company indicated a willingness to refund the investment, although no formal agreement had been reached as of late 2024.
=== In apple === Present in the chloroplasts and mitochondria of all parts of an apple, PPO is the major enzyme responsible for enzymatic browning of apples. Due to an increase in consumer demand for pre-prepared fruits and vegetables, a solution for enzymatic browning has been a targeted area of research and new product development. As an example, pre-sliced apples are an appealing consumer product, but slicing apples induces PPO activity, leading to browning of the cut surfaces and lowering their esthetic quality. Browning also occurs in apple juices and purees when poorly handled or processed. Arctic apples, an example of genetically modified fruit engineered to reduce PPO activity, are a suite of trademarked apples that contain a non-browning trait derived by gene silencing to suppress the expression of PPO, thus inhibiting fruit browning.
Sources: en.wikipedia.org
==== Covalently linked gels ==== Three-dimensional covalently linked polymer networks are insoluble in all solvents, they merely swell in good solvents. Thermoresponsive polymer gels show a discontinuous change of the degree of swelling with temperature. At the volume phase transition temperature (VPTT) the degree of swelling changes drastically. Researchers try to exploit this behavior for temperature-induced drug delivery. In the swollen state, previously incorporated drugs are released easily by diffusion. More sophisticated "catch and release" techniques have been elaborated in combination with lithography and molecular imprinting.
== Thermodynamics == The thermodynamics of metal ion complex formation provides much significant information. In particular it is useful in distinguishing between enthalpic and entropic effects. Enthalpic effects depend on bond strengths and entropic effects have to do with changes in the order/disorder of the solution as a whole. The chelate effect, below, is best explained in terms of thermodynamics. An equilibrium constant is related to the standard Gibbs free energy change for the reaction
=== Oxidation === Plasma processing, corona treatment, and flame treatment can all be classified as surface oxidation mechanisms. These methods all involve cleavage of polymer chains in the material and the incorporation of carbonyl, and hydroxyl functional groups. The incorporation of oxygen into the surface creates a higher surface energy allowing the substrate to be coated.
== Medical uses == Flupentixol's main use is as a long-acting injection given once in every two or three weeks to individuals with schizophrenia who have poor compliance with medication and have frequent relapses of illness, though it is also commonly given as a tablet. There is little formal evidence to support its use for this indication but it has been in use for over fifty years. Flupentixol is also used in low doses as an antidepressant. There is tentative evidence that it reduces the rate of deliberate self-harm, among those who self-harm repeatedly.
== Pharmacology == Taxifolin is not mutagenic and less toxic than the related compound quercetin. It acts as a potential chemopreventive agent by regulating genes via an ARE-dependent mechanism. Taxifolin has shown to inhibit the ovarian cancer cell growth in a dose-dependent manner. However, in this same study, taxifolin was the least effective flavonoid in the inhibition of VEGF expression. There is also a strong correlation (with a correlation coefficient of 0.93) between the antiproliferative effects of taxifolin derivatives on murine skin fibroblasts and human breast cancer cells. Taxifolin has shown to have anti-proliferative effects on many types of cancer cells by inhibiting cancer cell lipogenesis. By inhibiting the fatty acid synthase in cancer cells, taxifolin is able to prevent the growth and spread of cancer cells. Taxifolin also stops the effects of overexpression of P-glycoprotein, which prevents the development of chemoresistance. Taxifolin does this via inhibition of rhodamine 123 and doxorubicin. The capacity of taxifolin to stimulate fibril formation and promote stabilization of fibrillar forms of collagen can be used in medicine. Also taxifolin inhibited the cellular melanogenesis as effectively as arbutin, one of the most widely used hypopigmenting agents in cosmetics. Taxifolin also enhances the efficacy of conventional antibiotics such as levofloxacin and ceftazidime in vitro, which have potential for combinatory therapy of patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.